| Literature DB >> 27810898 |
Hyun Lee1, Jung-Jin Park1, Nga Nguyen1, Jun Sub Park1, Jin Hong1, Seung-Hyeob Kim1, Woon Young Song2, Hak Joong Kim2, Kwangman Choi3, Sungchan Cho3, Jae-Seon Lee4, Bong-Woo Kim5, Young-Gyu Ko6.
Abstract
Mitsugumin 53 (MG53) is an E3 ligase that interacts with and ubiquitinates insulin receptor substrate-1 (IRS-1) in skeletal muscle; thus, an MG53-IRS-1 interaction disruptor (MID), which potentially sensitizes insulin signaling with an elevated level of IRS-1 in skeletal muscle, is an excellent candidate for treating insulin resistance. To screen for an MID, we developed a bimolecular luminescence complementation system using an N-terminal luciferase fragment fused with IRS-1 and a C-terminal luciferase fragment fused with an MG53 C14A mutant that binds to IRS-1 but does not have E3 ligase activity. An MID, which was discovered using the bimolecular luminescence complementation system, disrupted the molecular association of MG53 with IRS-1, thus abolishing MG53-mediated IRS-1 ubiquitination and degradation. Thus, the MID sensitized insulin signaling and increased insulin-elicited glucose uptake with an elevated level of IRS-1 in C2C12 myotubes. These data indicate that this MID holds promise as a drug candidate for treating insulin resistance.Entities:
Keywords: diabetes; drug discovery; insulin receptor substrate 1 (IRS-1); insulin resistance; skeletal muscle
Mesh:
Substances:
Year: 2016 PMID: 27810898 PMCID: PMC5207173 DOI: 10.1074/jbc.M116.754424
Source DB: PubMed Journal: J Biol Chem ISSN: 0021-9258 Impact factor: 5.157